312 related articles for article (PubMed ID: 17441731)
21. New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein.
Labialle S; Dayan G; Gayet L; Rigal D; Gambrelle J; Baggetto LG
Nucleic Acids Res; 2004; 32(13):3864-76. PubMed ID: 15272088
[TBL] [Abstract][Full Text] [Related]
22. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
23. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
[TBL] [Abstract][Full Text] [Related]
24. N-ethylmaleimide increases P-glycoprotein photoaffinity labeling with iodoaryl-azidoprazosin in multidrug resistant cells.
Wang Y; Georges E
Anticancer Res; 1997; 17(1A):357-64. PubMed ID: 9066677
[TBL] [Abstract][Full Text] [Related]
25. Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1.
Kaszubiak A; Kupstat A; Müller U; Hausmann R; Holm PS; Lage H
Biochem Biophys Res Commun; 2007 May; 357(1):295-301. PubMed ID: 17418094
[TBL] [Abstract][Full Text] [Related]
26. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1.
Yagüe E; Higgins CF; Raguz S
Gene Ther; 2004 Jul; 11(14):1170-4. PubMed ID: 15164094
[TBL] [Abstract][Full Text] [Related]
27. RNA helicase A in the MEF1 transcription factor complex up-regulates the MDR1 gene in multidrug-resistant cancer cells.
Zhong X; Safa AR
J Biol Chem; 2004 Apr; 279(17):17134-41. PubMed ID: 14769796
[TBL] [Abstract][Full Text] [Related]
28. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.
Alemán C; Annereau JP; Liang XJ; Cardarelli CO; Taylor B; Yin JJ; Aszalos A; Gottesman MM
Cancer Res; 2003 Jun; 63(12):3084-91. PubMed ID: 12810633
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms.
Li X; Li JP; Yuan HY; Gao X; Qu XJ; Xu WF; Tang W
Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):607-17. PubMed ID: 18193112
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein.
Shi Z; Liang YJ; Chen ZS; Wang XH; Ding Y; Chen LM; Fu LW
Oncol Rep; 2007 Apr; 17(4):969-76. PubMed ID: 17342344
[TBL] [Abstract][Full Text] [Related]
31. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells.
Yu ST; Chen TM; Tseng SY; Chen YH
Biochem Biophys Res Commun; 2007 Jun; 358(1):79-84. PubMed ID: 17482571
[TBL] [Abstract][Full Text] [Related]
32. Immunotoxin resistance in multidrug resistant cells.
McGrath MS; Rosenblum MG; Philips MR; Scheinberg DA
Cancer Res; 2003 Jan; 63(1):72-9. PubMed ID: 12517780
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of P-glycoprotein but not its mRNA in multidrug resistant cells selected with hydroxyrubicin.
Zhao JY; Savaraj N; Song R; Priebe W; Kuo MT
Anticancer Res; 1994; 14(5A):1735-42. PubMed ID: 7531410
[TBL] [Abstract][Full Text] [Related]
34. Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA (siRNA) in leukemia cells.
Peng Z; Xiao Z; Wang Y; Liu P; Cai Y; Lu S; Feng W; Han ZC
Cancer Gene Ther; 2004 Nov; 11(11):707-12. PubMed ID: 15375375
[TBL] [Abstract][Full Text] [Related]
35. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
Majumder S; Dutta P; Mukherjee P; Datta ER; Efferth T; Bhattacharya S; Choudhuri SK
Cancer Lett; 2006 Nov; 244(1):16-23. PubMed ID: 16410038
[TBL] [Abstract][Full Text] [Related]
36. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
37. Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene.
Wei H; Su H; Bai D; Zhao H; Ge J; Wang B; Yao X; Ma L
Chin Med J (Engl); 2003 Nov; 116(11):1644-8. PubMed ID: 14642128
[TBL] [Abstract][Full Text] [Related]
38. Multidrug resistance of acute leukemia and a strategy to overcome it.
Motoji T; Motomura S; Wang YH
Int J Hematol; 2000 Dec; 72(4):418-24. PubMed ID: 11197207
[TBL] [Abstract][Full Text] [Related]
39. Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism.
Park S; James CD
Cancer Res; 2003 Feb; 63(3):723-7. PubMed ID: 12566319
[TBL] [Abstract][Full Text] [Related]
40. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression.
Bodey B; Taylor CR; Siegel SE; Kaiser HE
Anticancer Res; 1995; 15(6B):2461-8. PubMed ID: 8669809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
